{"id":"https://openalex.org/W7204862723","doi":"https://doi.org/10.1016/j.bioorg.2026.110460","title":"Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors","display_name":"Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors","publication_year":2026,"publication_date":"2026-09-01","ids":{"openalex":"https://openalex.org/W7204862723","doi":"https://doi.org/10.1016/j.bioorg.2026.110460","pmid":"https://pubmed.ncbi.nlm.nih.gov/42691879"},"language":"en","primary_location":{"id":"doi:10.1016/j.bioorg.2026.110460","doi":"https://doi.org/10.1016/j.bioorg.2026.110460","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bioorg.2026.110460","pdf_url":null,"source":{"id":"https://openalex.org/S165482960","display_name":"Bioorganic Chemistry","issn_l":"0045-2068","issn":["0045-2068","1090-2120"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5128732878","display_name":"Naglaa M. Ahmed","orcid":"https://orcid.org/0000-0001-5864-2370","observed_orcids":["https://orcid.org/0000-0001-5864-2370"]},"institutions":[{"id":"https://openalex.org/I84058292","display_name":"Helwan University","ror":"https://ror.org/00h55v928","country_code":"EG","type":"education","lineage":["https://openalex.org/I84058292"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Naglaa M. Ahmed","raw_affiliation_strings":["Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt","institution_ids":["https://openalex.org/I84058292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080163606","display_name":"Rizk Elsayed Khidre","orcid":"https://orcid.org/0000-0002-2317-8683","observed_orcids":["https://orcid.org/0000-0002-2317-8683","https://orcid.org/0000-0001-6693-5130"]},"institutions":[{"id":"https://openalex.org/I4210131959","display_name":"National Research Centre","ror":"https://ror.org/02n85j827","country_code":"EG","type":"facility","lineage":["https://openalex.org/I4210131959"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Rizk E. Khidre","raw_affiliation_strings":["Chemical Industry Research Institute, National Research Centre (NRC), 12622, Dokki, Giza, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemical Industry Research Institute, National Research Centre (NRC), 12622, Dokki, Giza, Egypt","institution_ids":["https://openalex.org/I4210131959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148886652","display_name":"Mohamed R. Khidre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145487455","display_name":"Cairo University","ror":"https://ror.org/03q21mh05","country_code":"EG","type":"education","lineage":["https://openalex.org/I145487455"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Mohamed R. Khidre","raw_affiliation_strings":["Faculty of Medicine, Cairo University, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine, Cairo University, Cairo, Egypt","institution_ids":["https://openalex.org/I145487455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032387955","display_name":"Ahmed El-morsy","orcid":"https://orcid.org/0000-0003-1549-7673","observed_orcids":["https://orcid.org/0000-0003-1549-7673"]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]},{"id":"https://openalex.org/I4405259362","display_name":"Islamic University of Najaf","ror":"https://ror.org/024dzaa63","country_code":"IQ","type":"education","lineage":["https://openalex.org/I4405259362"]}],"countries":["EG","IQ"],"is_corresponding":false,"raw_author_name":"Ahmed El-morsy","raw_affiliation_strings":["Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf, Iraq"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf, Iraq","institution_ids":["https://openalex.org/I184834183","https://openalex.org/I4405259362"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063279652","display_name":"Tamer Nasr","orcid":"https://orcid.org/0000-0003-0104-9765","observed_orcids":["https://orcid.org/0000-0003-0104-9765"]},"institutions":[{"id":"https://openalex.org/I32619867","display_name":"Egypt-Japan University of Science and Technology","ror":"https://ror.org/02x66tk73","country_code":"EG","type":"education","lineage":["https://openalex.org/I32619867"]},{"id":"https://openalex.org/I84058292","display_name":"Helwan University","ror":"https://ror.org/00h55v928","country_code":"EG","type":"education","lineage":["https://openalex.org/I84058292"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Tamer Nasr","raw_affiliation_strings":["Medicinal Chemistry Department, Faculty of Pharmacy, Egypt-Japan University of Science and Technology (E-JUST), P.O. 21934 Alexandria, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Chemistry Department, Faculty of Pharmacy, Egypt-Japan University of Science and Technology (E-JUST), P.O. 21934 Alexandria, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt","institution_ids":["https://openalex.org/I32619867","https://openalex.org/I84058292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066270766","display_name":"Khaled El\u2010Adl","orcid":"https://orcid.org/0000-0002-8922-9770","observed_orcids":["https://orcid.org/0000-0002-8922-9770"]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]},{"id":"https://openalex.org/I3130228804","display_name":"Heliopolis University","ror":"https://ror.org/02tme6r37","country_code":"EG","type":"education","lineage":["https://openalex.org/I3130228804"]}],"countries":["EG"],"is_corresponding":true,"raw_author_name":"Khaled El-Adl","raw_affiliation_strings":["Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. Electronic address: eladlkhaled74@azhar.edu.eg"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. Electronic address: eladlkhaled74@azhar.edu.eg","institution_ids":["https://openalex.org/I184834183","https://openalex.org/I3130228804"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067338844","display_name":"Noura S. Hanafy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3130228804","display_name":"Heliopolis University","ror":"https://ror.org/02tme6r37","country_code":"EG","type":"education","lineage":["https://openalex.org/I3130228804"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Noura S. Hanafy","raw_affiliation_strings":["Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt","institution_ids":["https://openalex.org/I3130228804"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5066270766"],"corresponding_institution_ids":["https://openalex.org/I184834183","https://openalex.org/I3130228804"],"apc_list":{"value":4240,"currency":"USD","value_usd":4240},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"182","issue":null,"first_page":"110460","last_page":"110460"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegfr-2-inhibitors","display_name":"VEGFR-2 inhibitors","score":0.8629999756813049},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/dual-kinase-inhibitors","display_name":"dual kinase inhibitors","score":0.8700000047683716},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.9010000228881836},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7110000252723694},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.9670000076293945},{"id":"https://openalex.org/keywords/admet-properties","display_name":"ADMET properties","score":0.6029999852180481},{"id":"https://openalex.org/keywords/molecular-docking","display_name":"molecular docking","score":0.8230000138282776},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.5509999990463257},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.41600000858306885},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/cancer-cell-lines","display_name":"cancer cell lines","score":0.5379999876022339},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.5210000276565552},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.8920000195503235},{"id":"https://openalex.org/keywords/drug-design","display_name":"drug design","score":0.33500000834465027}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8417999744415283},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.8220000267028809},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7710000276565552},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.6101999878883362},{"id":"https://openalex.org/C2780783641","wikidata":"https://www.wikidata.org/wiki/Q738686","display_name":"MTT assay","level":3,"score":0.5681999921798706},{"id":"https://openalex.org/C89138240","wikidata":"https://www.wikidata.org/wiki/Q3066564","display_name":"Vero cell","level":3,"score":0.5666999816894531},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.5062000155448914},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.4691999852657318},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4691999852657318},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4564000070095062},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4375999867916107},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.42890000343322754},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.3555999994277954},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.34459999203681946},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.3418000042438507},{"id":"https://openalex.org/C2994372470","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell lines","level":4,"score":0.33899998664855957},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3301999866962433},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.3199999928474426},{"id":"https://openalex.org/C2777752112","wikidata":"https://www.wikidata.org/wiki/Q903238","display_name":"Lead compound","level":3,"score":0.3158000111579895},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3068000078201294},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.30090001225471497},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.29010000824928284},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.2870999872684479},{"id":"https://openalex.org/C3018146709","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Anticancer drug","level":3,"score":0.2840999960899353},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.27619999647140503},{"id":"https://openalex.org/C33618052","wikidata":"https://www.wikidata.org/wiki/Q6013136","display_name":"In vitro toxicology","level":3,"score":0.2721000015735626},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.26570001244544983},{"id":"https://openalex.org/C2779448499","wikidata":"https://www.wikidata.org/wiki/Q1227206","display_name":"Oxadiazole","level":2,"score":0.2639000117778778},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.26260000467300415}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D002522","descriptor_name":"Chlorocebus aethiops","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004354","descriptor_name":"Drug Screening Assays, Antitumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D062105","descriptor_name":"Molecular Docking Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.bioorg.2026.110460","doi":"https://doi.org/10.1016/j.bioorg.2026.110460","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bioorg.2026.110460","pdf_url":null,"source":{"id":"https://openalex.org/S165482960","display_name":"Bioorganic Chemistry","issn_l":"0045-2068","issn":["0045-2068","1090-2120"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic Chemistry","raw_type":"journal-article"},{"id":"pmid:42691879","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42691879","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":61,"referenced_works":["https://openalex.org/W1416958482","https://openalex.org/W1557061959","https://openalex.org/W1608710587","https://openalex.org/W1964596754","https://openalex.org/W1965136295","https://openalex.org/W1974903851","https://openalex.org/W1979449084","https://openalex.org/W1983790923","https://openalex.org/W1992905076","https://openalex.org/W2009867031","https://openalex.org/W2057166163","https://openalex.org/W2061345986","https://openalex.org/W2063027760","https://openalex.org/W2063373049","https://openalex.org/W2065240552","https://openalex.org/W2079398727","https://openalex.org/W2086528927","https://openalex.org/W2110212700","https://openalex.org/W2114918609","https://openalex.org/W2132395321","https://openalex.org/W2411726279","https://openalex.org/W2473281810","https://openalex.org/W2519105450","https://openalex.org/W2723466115","https://openalex.org/W2733738915","https://openalex.org/W2747651708","https://openalex.org/W2775040114","https://openalex.org/W2796295138","https://openalex.org/W2912206665","https://openalex.org/W2940507061","https://openalex.org/W3033659767","https://openalex.org/W3044204858","https://openalex.org/W3081848457","https://openalex.org/W3082029771","https://openalex.org/W3083138156","https://openalex.org/W3092270666","https://openalex.org/W3157992644","https://openalex.org/W3183173575","https://openalex.org/W3193974056","https://openalex.org/W4212872812","https://openalex.org/W4225325549","https://openalex.org/W4241840908","https://openalex.org/W4242372416","https://openalex.org/W4294170359","https://openalex.org/W4297546905","https://openalex.org/W4308748367","https://openalex.org/W4309438082","https://openalex.org/W4315648150","https://openalex.org/W4320716728","https://openalex.org/W4366313442","https://openalex.org/W4372334222","https://openalex.org/W4381194625","https://openalex.org/W4382394156","https://openalex.org/W4384030293","https://openalex.org/W4385841474","https://openalex.org/W4398206684","https://openalex.org/W4403199546","https://openalex.org/W4404919389","https://openalex.org/W4415493554","https://openalex.org/W4415601289","https://openalex.org/W7118001277"],"related_works":["https://openalex.org/W4381194625","https://openalex.org/W3157992644","https://openalex.org/W3002443851","https://openalex.org/W4390202084","https://openalex.org/W4412422634","https://openalex.org/W4309438082","https://openalex.org/W4406961227","https://openalex.org/W4415130889","https://openalex.org/W4396807757","https://openalex.org/W4317871089"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2026-09-02T00:00:00"}